<DOC>
	<DOCNO>NCT00543296</DOCNO>
	<brief_summary>The purpose study collect data patient severe uveitis require re-implantation sustained-release fluocinolone drug delivery device due depletion study drug previous implanted device .</brief_summary>
	<brief_title>Re-implantation Fluocinolone Acetonide Implant Non-infectious Uveitis Affecting Posterior Segment</brief_title>
	<detailed_description>Purpose : To collect medical information sustain release drug delivery system delivers corticosteroid , fluocinolone acetonide , directly vitreous cavity eye . This system potential maintain therapeutic drug level eye reduce systemic exposure drug negligible level . RetisertTM trade name intravitreal fluocinolone acetonide implant . Hypothesis : The RetisertTM safe effective method manage patient severe uveitis</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Fluocinolone Acetonide</mesh_term>
	<criteria>Noninfectious intermediate , posterior panuveitis Previous placement fluocinolone acetonide implant initial uveitis quiescence subsequent recurrence inflammation implant deplete drug Infectious uveitis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>uveitis</keyword>
	<keyword>Cystoid Macular Edema ( CME )</keyword>
	<keyword>fluocinolone acetonide</keyword>
	<keyword>non-infectious uveitis affect posterior segment</keyword>
</DOC>